The adverse events were few with cumulative doses as high as 1,360 mg/m2. These cases show that pegylated liposomal doxorubicin may be a promising agent in recurrent ovarian carcinoma. We recognize the limitations of our data. The results need to be confirmed in a larger group of patients.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/03/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/16353663